Insights

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

  • Turning Treatment Barriers into Drivers

    Improved compliance and adherence can lead to better health outcomes for patients and brand growth for drug manufacturers, but convincing patients to accept treatment is a well-recognized challenge.

  • The Costly Impact of Implicit Questions

    Learn about a dangerous, hidden communication challenge facing patients and their healthcare providers. Then uncover ways for your brand to offer support by helping put patients on a path towards activation and adherence.

  • The Definitive Guide to Dialogue Research

    Whether you’re new to healthcare dialogue research or consider yourself an expert, the Definitive Guide to Dialogue Research will help you discover how natural exam-room conversations can be applied to build a stronger foundation for your brand marketing goals.

  • SALES FORCE REPORT: THE ONLINE REP

    Just a few short years ago most doctors were technophobic. You would have been hard-pressed to get a physician to consider electronic prescribing or logging-on to web-based medical conference. What a difference a few years can make. According to Manhattan…

  • MEDADNEWS: CLINIC-SPECIFIC WEBSITES ON THE RISE

    In the upcoming November issue of Med Ad News, our sales-force effectiveness series continues with a technology round up, providing a catalogue of new and upgraded tech solutions for pharma sales forces. But technology is not only connecting healthcare professionals…

  • PATIENT MARKETING REPORT: GROUP THERAPY

    It doesn’t take several years of post-graduate studies and a degree in medicine to describe what it’s like to live with a disease. From a patient’s perspective, the practical wisdom available in an embar-rassing anecdote, or a triumphant description of…

  • Verilogue logo

    PRESENTATION OF VERILOGUE DATA AT UPCOMING EYE FOR PHARMA CONFERENCE REVEALS HOW TO IDENTIFY AND OVERCOME PATIENT ADHERENCE CHALLENGES

    WHO: Jeffrey Dierks, Senior Product Director, Endo Pharmaceuticals WHAT: “Adherence as part of a commercial strategy: How to create value through communication and co-ordination, leading to better relationships with patients” This presentation will include information that demonstrates how the analysis of…

  • TRACKING THE EVOLUTION OF ONCOLOGY DRUG PRESCRIBING

    Do you know what your cancer drug is up to? Answering that question is not as simple as for medicines taken by well-defined patient groups, or principally for one disease. Yet among drug classes oncology treatments hold a unique position:…

  • MEDADNEWS: LITTLE EMPATHY FOR SIDE EFFECT FEARS

    Generalized fears about taking medications are common among patients, according to a new study issued by Verilogue exploring the actual fears and concerns patients most frequently discuss in their doctors’ offices and how doctors respond to them. The review of…

  • MEDADNEWS: SPECIALTY REPS: THE SMALLER, SMARTER SALES FORCE

    The pharmaceutical sales force is undergoing a dra-matic evolution as the pharmaceutical industry shifts from pri-mary-care drugs to biotechnology and specialist medicines. To effectively promote this changing product mix, marketers must adapt their sales and marketing models. In particular, marketers…

  • FDA FILES: A MORE TRANSPARENT FDA

    FDA is under new management. Margaret Hamburg, M.D., was sworn in to her position as FDA commissioner May 22, 2009, by Health and Human Services Secretary Kathleen Sebelius. Dr. Hamburg is an authority on global health,public health systems, infectious disease,…

  • MEDADNEWS: PHYSICIANS DRIVE VACCINE DIALOGUE

    Vaccines are anticipated to be one of the fastest-growing segments of the pharmaceutical market between 2008 and 2023. Analysts believe that new legislation, advancements in science, and enhanced vaccine awareness are contributing to vaccines growth, particularly in the United States.…

  • VERILOGUE FEATURED IN BUSINESS WEEK ONLINE

    Don’t spend precious resources wooing early-stage investors. First build your business, then seek funding that can help you grow It’s the ongoing irony of early-stage investing: Just when your little-engine-that-could startup desperately needs funding, sophisticated investors have no interest in…